Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

VVC Exploration delays financial filings due to valuation issues, seeks capital to support operations.

Market News
16 May 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

VVC Exploration Corporation has applied for a Management Cease Trade Order (MCTO) due to a delay in filing its audited financial statements for the fiscal year ending January 31, 2026. The delay stems from valuation uncertainties related to its investment in Cyber Apps Solutions Corp., which is undergoing foreclosure and management changes. VVC is conducting an independent asset valuation and expects to file the reports by June 30, 2026. Meanwhile, the company is pursuing new financing options to support its core helium and gold exploration projects, though any financing is subject to restrictions under the MCTO.

More News

Nuvei to acquire Payoneer for $2.75B, boosting global payment platform capabilities.

Nuvei to acquire Payoneer for $2.75B, boosting global payment platform capabilities.

Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...

Company Fundamentals
Bullish
1 hour ago
Eli Lilly's leukemia drug combo cuts disease progression risk by 45% in Phase 3 trial

Eli Lilly's leukemia drug combo cuts disease progression risk by 45% in Phase 3 trial

Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...

Market News
Bullish
1 hour ago
Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

Osteoarthritis market to grow 3% CAGR through 2036, fueled by new therapies and rising disease cases

The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...

Market News
Bullish
1 hour ago
Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

Class action filed against Nano-X for alleged securities fraud, investors urged to join by Aug 11, 2026.

A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...

Market News
Bearish
1 hour ago
Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharma shares rise after positive 6-month data on obesity drug setmelanotide in Prader-Willi syndrome patients.

Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App